Key result
Atrioventricular valve repair during the Fontan operation shows no mortality benefit over no repair.
Why the study?
The prevalence, impact, and outcome of atrioventricular valve regurgitation repair in Fontan patients were not well characterized.
Does atrioventricular valve repair improve survival or reduce regurgitation in patients with atrioventricular valve regurgitation undergoing the modified Fontan operation?
Cohort (n=328)
Does atrioventricular valve repair improve survival or reduce regurgitation in patients with atrioventricular valve regurgitation undergoing the modified Fontan operation?
Absolute Event Rate: 18.9% vs 10.9%
p-value: p=0.16
Atrioventricular valve repair during the Fontan operation for moderate to severe regurgitation does not provide additional benefit over the Fontan operation alone in improving regurgitation or long-term survival.
AV valve repair during Fontan showed no survival benefit; leaves open its effect on regurgitation, warranting prospective trials.
OBJECTIVE: To evaluate the prevalence, impact and outcome of repair of atrioventricular valve regurgitation (AVVR) in Fontan patients. METHODS: We retrospectively reviewed 340 Fontan patients from 1986 to 2001. Twelve patients with valve closure or replacements were excluded. AVVR was graded by transthoracic echocardiography. Patients were divided into group O (no AVVR), group A (1+ to 2+) and group B (3+ to 4+). RESULTS: AVVR was present in 129 (39.3%) patients. Repair was carried out in 37 (11.3%) with no difference in mortality as compared to no repair (18.9 vs 10.9%, P =0.16). Mean follow-up was 44 months (1-197 months) with 14 patients lost to follow-up. No valve repair was carried out in group O (192 patients) and no clinical change in AVVR was observed (pre-op 0.00, post-op 0.78). In group A (85 patients) 6 patients had valve repair without significant change in the degree of AVVR after valve repair (pre-op 1.8, post-op 2.2, P = 0.18). In group B (44 patients) 31 had valve repair and a significant reduction was observed (pre-op 3.28, post-op 2.44, P < 0.001). A similar improvement was also observed when the valve was not repaired (pre-op 3.25, post-op 2.44, P = 0.003). Survival at 10 years was comparable (83% repaired, 89% not repaired, P = 0.165). There was no difference in the incidence of long-term complications (26% repaired, 29.7% no repair, P = 0.64). CONCLUSIONS: Trivial to mild AVVR remains stable and their repair during the Fontan operation provides no additional benefits. Valve repair in patients with moderate to severe AVVR improved the regurgitation with comparable operative mortality and long-term outcome; however, similar benefits could be achieved without repair of the atrioventricular valve. We should not deny patients with similar AVVR the Fontan operation.
No takes yet. Share an insight, caveat, or question.
Sallehuddin et al. (2004) conducted a cohort in Atrioventricular valve regurgitation in Fontan patients (n=328). Atrioventricular valve repair vs. No valve repair was evaluated on Mortality (p=0.16). Repair of atrioventricular valve regurgitation during the Fontan operation yielded no significant difference in mortality compared to no repair (18.9% vs 10.9%, P=0.16).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: